Skip to main content

Table 2 Univariate and multivariate analyses of the predictors for mortality during treatment of tigecycline or sulbactam or ampicillin/sulbactam for pneumonia involving multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (MDR Acb) complex

From: Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex

Variables Deceaseda Survivorsa Univariate Multivariateb
n = 36 n = 132 p p Adjusted OR (95 % CI)
Demographic parameters
 Age, yr 69.8 (14.7) 70.2 (16.0) 0.658   
 Male gender 26 (72.2) 89 (67.4) 0.583   
Concomitant diseases
 Hepatic dysfunction 6 (16.7) 12 (9.1) 0.224   
 Renal insufficiency 15 (41.7) 49 (37.1) 0.619   
 Chronic pulmonary disease 6 (16.7) 36 (27.3) 0.193   
 Heart disease 6 (16.7) 14 (10.6) 0.383   
 Diabetes mellitus 14 (38.9) 47 (35.6) 0.717   
 Immune compromise 5 (13.9) 19 (14.4) 0.939   
 Malignancy 11 (30.6) 24 (18.2) 0.105   
Surgery 11 (30.6) 26 (19.7) 0.163   
Clinical conditions
 APACHE II Score 20.3 (7.3) 20.1 (5.8) 0.858   
 Ventilator use 26 (72.2) 107 (81.1) 0.247   
 Bilateral pneumonia 30 (83.3) 88 (66.7) 0.053 0.047 2.717 (1.015–7.272)
 Polymicrobial pneumonia 29 (80.6) 99 (75.0) 0.488   
  With MRSA 10 (27.8) 50 (37.9) 0.262   
  With Pseudomonas aeruginosa 14 (38.9) 42 (31.8) 0.425   
  With Klebsiella spp. 6 (16.7) 11 (8.3) 0.207   
  With Serratia marcescens 3 (8.3) 8 (6.1) 0.704   
  With Stenotrophomanas maltophilia 6 (16.7) 15 (11.4) 0.400   
 Multisite infections 18 (50.0) 50 (37.9) 0.189   
  With urinary tract infection 8 (22.2) 24 (18.2) 0.584   
  With catheter related infection 2 (5.6) 10 (7.6) 1.000   
  With skin and soft tissue infection 6 (16.7) 9 (6.8) 0.094 0.214 2.070 (0.657–6.521)
  With intra-abdominal infection 3 (8.3) 9 (6.8) 0.721   
  With invasive fungal infection 3 (8.3) 13 (9.8) 1.000   
Microbiology
 MDR Acb complex with TG or SB resistancec 7 (19.4) 52 (39.4) 0.026 0.079 0.426 (0.164–1.103)
 Airway eradication of MDR Acb complexd 11 (42.3) 62 (49.2) 0.521   
 Bacteremia during treatment 2 (5.6) 2 (1.5) 0.201   
Treatment
 Tigecycline-based treatment 21 (58.3) 63 (47.7) 0.259 0.451 1.371 (0.604–3.116)
 Duration, days 15.6 (7.9) 15.5 (6.2) 0.519   
 Combination therapy 25 (69.4) 91 (68.9) 0.954   
  With cephalosporins 6 (16.7) 22 (16.7) 1.000   
  With carbapenems 12 (33.3) 53 (40.2) 0.457   
  With fluoroquinolones 2 (5.6) 14 (10.6) 0.527   
  With colistin 3 (8.3) 9 (6.8) 0.721   
 Delayed treatment 9 (25.0) 48 (36.4) 0.202   
  1. Abbreviations: MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii, OR odd ratio, CI confidence interval, APACHE acute physiology and chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, TG tigecycline, SB sulbactam
  2. aCategorical data are no. (%) of subject, continuous data are expressed as mean (standard deviation)
  3. bAll variables included in the final multivariable model are shown
  4. c The initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
  5. d26 patients in the deceased group and 126 in the survivors group had available data for evaluation